NASDAQ:OPNTOpiant Pharmaceuticals Stock Price, Forecast & News

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPNT shares have increased by 2.4% and is now trading at $11.11. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opiant Pharmaceuticals.

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Opiant Pharmaceuticals.

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its quarterly earnings data on Tuesday, May, 12th. The technology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.21. The technology company earned $4.28 million during the quarter, compared to analysts' expectations of $4.63 million. Opiant Pharmaceuticals had a net margin of 29.58% and a return on equity of 3.27%. View Opiant Pharmaceuticals' earnings history.

1 Wall Street analysts have issued twelve-month target prices for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 278.0% from the stock's current price. View analysts' price targets for Opiant Pharmaceuticals.

Media headlines about OPNT stock have trended somewhat negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned media headlines about the technology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutOpiant Pharmaceuticals.

Opiant Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 3,200 shares, a decrease of 5.9% from the April 15th total of 3,400 shares. Based on an average daily trading volume, of 18,400 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the company are short sold. View Opiant Pharmaceuticals' Current Options Chain.

Some companies that are related to Opiant Pharmaceuticals include Rubicon Minerals (RBYCF), Fission Uranium (FCUUF), Mountain Province Diamonds (MPVDF), Amerigo Resources (ARREF), Atlatsa Resources (ATLRF), Santa Fe Gold (SFEG), Pacific Booker Minerals (PBMLF), US Gold (USAU), Bullfrog Gold (BFGC), Dakota Territory Resource (DTRC), Silver Bull Resources (SVBL), Avalon Advanced Materials (AVLNF), Quantum Materials (QTMM), Westwater Resources (WWR) and Wealth Minerals (WMLLF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Synchrony Financial (SYF), Vodafone Group (VOD), Cyberark Software (CYBR), AT&T (T), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Vodafone Group (VOD) and Agenus (AGEN).

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Opiant Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (8.95%), Fondren Management LP (7.38%), BlackRock Inc. (0.49%), Mesirow Financial Investment Management Inc. (0.48%), Alambic Investment Management L.P. (0.36%) and Wedge Capital Management L L P NC (0.30%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick and Roger Crystal. View institutional ownership trends for Opiant Pharmaceuticals.

OPNT stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, and BlackRock Inc.. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Michael Sinclair, and Phil Skolnick. View insider buying and selling activity for Opiant Pharmaceuticals.

OPNT stock was purchased by a variety of institutional investors in the last quarter, including Fondren Management LP, Stonepine Capital Management LLC, Mesirow Financial Investment Management Inc., Alambic Investment Management L.P., Acadian Asset Management LLC, Advisor Group Holdings Inc., and Morgan Stanley. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole, and Gabrielle Alison Silver. View insider buying and selling activity for Opiant Pharmaceuticals.

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $11.11.

Opiant Pharmaceuticals has a market capitalization of $47.33 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.

The official website for Opiant Pharmaceuticals is www.opiant.com.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]